Immunization Against Dengue Virus Infection is Coercive: A Timely Call

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2024 Jun 7

PMID 38845788

Authors

Iftekhar Ahmed

Rayhan Ahamed

Shamsun Nahar

Lazima F Bari

Syed M R Dewan

Affiliations

Soon will be listed here.

Abstract

Background: In context, the dengue virus causes dengue fever, which is spread by mosquito bites. About 22,000 people every year lose their lives as a direct result of it. Dengue fever has been on the rise recently, and its spread has alarmed health officials throughout the world.

Discussion: Vaccination is essential for the prevention and management of dengue cases because there is currently no particular cure against dengue virus. The current dengue epidemic calls for urgent action in the form of immunization. However, there are serious drawbacks to using existing vaccines like Dengvaxia. Besides, the Qdenga vaccine has not yet been approved by the FDA in the United States. On the other hand, positive results from a phase II randomized and controlled clinical study of the TV005 tetravalent live-attenuated dengue vaccine were recently reported in Bangladesh. Only an effective vaccination can drastically lower dengue infection and mortality rates.

Conclusion: The development of safe and effective vaccination, as well as their correct dissemination, is an essential requirement for the people of Bangladesh and the rest of the globe, and we concentrated on this critical problem in this article.

Citing Articles

Dengue fever in hyperglycemic patients: an emerging public health concern demanding eyes on the effective management strategies.

Shawon S, Hamid M, Ahmed H, Khan S, Dewan S Health Sci Rep. 2024; 7(10):e70144.

PMID: 39421212 PMC: 11483528. DOI: 10.1002/hsr2.70144.

(Burm. f.) Lindau Extract Inhibits Dengue Virus Infection and Inflammation in the Huh7 Hepatoma Cell Line.

Jantakee K, Panwong S, Sattayawat P, Sumankan R, Saengmuang S, Choowongkomon K Antibiotics (Basel). 2024; 13(8).

PMID: 39200005 PMC: 11350823. DOI: 10.3390/antibiotics13080705.

References

Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P . Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019; 381(21):2009-2019. DOI: 10.1056/NEJMoa1903869. View

Rahman M, Sobur M, Islam M, Ievy S, Hossain M, El Zowalaty M . Zoonotic Diseases: Etiology, Impact, and Control. Microorganisms. 2020; 8(9). PMC: 7563794. DOI: 10.3390/microorganisms8091405. View

Sunkara H, Dewan S . Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management. Int Immunopharmacol. 2021; 99:108049. PMC: 8343371. DOI: 10.1016/j.intimp.2021.108049. View

Rodrigues C, Plotkin S . Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol. 2020; 11:1526. PMC: 7371956. DOI: 10.3389/fmicb.2020.01526. View

Das P, Khan S, Rahman J, Dewan S . Effective Preventative Measures are Essential to Lower Disease Burden From Dengue and COVID-19 Co-infection in Bangladesh. Environ Health Insights. 2023; 17:11786302231212774. PMC: 10685758. DOI: 10.1177/11786302231212774. View

Nazmunnahar , Ahmed I, Islam M . Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report. Health Sci Rep. 2023; 6(3):e1127. PMC: 9981880. DOI: 10.1002/hsr2.1127. View

Chan C, Ooi E . Dengue: an update on treatment options. Future Microbiol. 2015; 10(12):2017-31. DOI: 10.2217/fmb.15.105. View

Pierce K, Durbin A, Walsh M, Carmolli M, Sabundayo B, Dickson D . TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies. J Clin Invest. 2023; 134(3). PMC: 10836801. DOI: 10.1172/JCI173328. View

Ooi E, Gubler D . Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publica. 2009; 25 Suppl 1:S115-24. DOI: 10.1590/s0102-311x2009001300011. View

10.

Mallapaty S . Dengue vaccine poised for roll-out but safety concerns linger. Nature. 2022; 611(7936):434-435. DOI: 10.1038/d41586-022-03546-2. View

11.

Gubler D . Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998; 11(3):480-96. PMC: 88892. DOI: 10.1128/CMR.11.3.480. View

12.

Thomas S, Yoon I . A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. 2019; 15(10):2295-2314. PMC: 6816420. DOI: 10.1080/21645515.2019.1658503. View

13.

Wilder-Smith A . The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh. Lancet Infect Dis. 2023; 24(2):112-113. DOI: 10.1016/S1473-3099(23)00565-0. View

14.

Roy S, Bhattacharjee S . Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021; 67(10):687-702. DOI: 10.1139/cjm-2020-0572. View

15.

Khosavanna R, Kareko B, Brady A, Booty B, Nix C, Lyski Z . Clinical Symptoms of Dengue Infection among Patients from a Non-Endemic Area and Potential for a Predictive Model: A Multiple Logistic Regression Analysis and Decision Tree. Am J Trop Med Hyg. 2020; 104(1):121-129. PMC: 7790069. DOI: 10.4269/ajtmh.20-0192. View

16.

Nasim R, Tisha J, Dewan S . Only COVID-19 and not all infectious diseases are of concern: A timely observation. Health Sci Rep. 2023; 6(9):e1589. PMC: 10519133. DOI: 10.1002/hsr2.1589. View